McDermott Will & Emery and Gantey advised GeNeuro on the deal.
GeNeuro, a Swiss company listed on the regulated market of Euronext Paris, completed its €17.5 million capital increase realized by way of an international private placement of new shares to qualified institutional investors.
GeNeuro is a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases.
Bryan, Garnier & Co Limited acted as Sole Book Runner on the private placement and a prospectus was approved on January 31, 2020 by the French Autorité des marchés financiers in relation to the listing of the newly issued shares.
McDermott Will & Emery acted for GeNeuro with a team led in Paris by partner David Revcolevschi (corporate/capital markets; Picture).
In Geneva, the law firm Gantey advised GeNeuro on the Swiss law aspects with partners Christophe Buchwalder and Natasa Markovic.
Clients: Geneuro SA;